Achondroplasia therapy reference (2026)

Achondroplasia care in 2026 organises around several integrated dimensions.

Disease-modifying therapy: vosoritide is a daily subcutaneous injection approved in children with achondroplasia from 4 months of age to growth plate closure. It increases growth velocity and is associated with improved body proportions and reduced craniocervical narrowing. Real-world evidence is accumulating on long-term growth, bone outcomes, and complications.

Surveillance: structured monitoring for the complications of achondroplasia is part of comprehensive care. Foramen magnum imaging in infancy to identify craniocervical compression. Spinal monitoring across childhood and adulthood for spinal stenosis and other complications. Otolaryngology assessment for sleep-disordered breathing and middle ear issues. Dental and orthodontic care.

Surgical care: decompression surgery for craniocervical compression in selected patients. Spinal surgery for spinal stenosis or other complications. Limb-lengthening surgery (controversial; choice is highly individualised and discussion-rich).

Emerging tier: follow-on CNP analogue programs (potentially with longer dosing intervals or oral formulations) are in late-stage trials. FGFR3-targeted programs (small-molecule FGFR3 inhibitors, monoclonal antibodies targeting FGFR3 signalling) are reading out.

The care-pathway question matters. Comprehensive achondroplasia care benefits from specialist multidisciplinary centres (skeletal dysplasia centres of excellence) that bring together genetics, paediatric orthopaedics, neurosurgery, otolaryngology, and other specialties. Access to such centres remains uneven.